Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02291003 · ClinicalTrials.gov registry record

Identification of Novel Circadian Biomarkers

A clinical trial, sponsored by Northwestern University.

Completed
Registry status
3
Enrollment target

NCT02291003 is a clinical trial that has completed, run by Northwestern University. The registered enrollment target is 3 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02291003 has completed, sponsored by Northwestern University.

COMPLETED
Registry status
3 participants
Enrollment target

Study Summary

Circadian clocks are not only found in discrete areas of the brain, but are found in virtually every organ in our bodies, including the heart, lungs and immune system. Disruptions in circadian clocks, or chronopathology, may underlie various forms of cardiovascular, pulmonary, and metabolic disorders. Over the past two decades, molecular geneticists have "cracked" the clock to reveal its core biochemical mechanisms evident in organisms from fruit flies to humans. These mechanistic insights have led to the discovery of links between clock function and an ever-expanding array of prevalent diseases, including heart, lung, metabolic and sleep disorders. Yet the prevalence of circadian disruption in these patient populations is unclear because current tests are not easily applied in clinical settings or have yet to be developed. Here the investigators exploit our newfound understanding of clock mechanisms and the development of new genomic technologies to identify novel complements of clock-regulated genes ("signatures") that will reveal the state of the internal biological clock. This approach will allow us to take a genomic snapshot of clock status from a single blood draw, substantially easing the diagnosis of these individuals with evidence of circadian disruption or misalignment, i.e., chronopathology.

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2015-01-29
Est. Completion 2017-09-30

Sponsor

Northwestern University

1,209 total trials

What the Registry Record Tells You About NCT02291003

The ClinicalTrials.gov registry entry for NCT02291003 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT02291003 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02291003 about?

NCT02291003 is a clinical study titled "Identification of Novel Circadian Biomarkers". Circadian clocks are not only found in discrete areas of the brain, but are found in virtually every organ in our bodies, including the heart, lungs and immune system. Disruptions in circadian clocks, or chronopathology, may underlie various forms of cardiovascular, pulmonary, and metabolic disorder...

What is the current status of trial NCT02291003?

This trial is currently completed. The enrollment target is 3 participants. The study started on 2015-01-29. Estimated completion is 2017-09-30.

Who is sponsoring clinical trial NCT02291003?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.